{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:47:16Z","timestamp":1792601236979,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Cognitive practice effects (PEs) can delay detection of progression from cognitively unimpaired to mild cognitive impairment (MCI). They also reduce diagnostic accuracy as suggested by biomarker positivity data. Even among those who decline, PEs can mask steeper declines by inflating cognitive scores. Within MCI samples, PEs may increase reversion rates and thus impede detection of further impairment. Within an MCI sample at baseline, we evaluated how PEs impact prevalence, reversion rates, and dementia progression after 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined 329 baseline Alzheimer\u2019s Disease Neuroimaging Initiative MCI participants (mean age = 73.1; <jats:italic>SD<\/jats:italic> = 7.4). We identified test-na\u00efve participants who were demographically matched to returnees at their 1-year follow-up. Since the only major difference between groups was that one completed testing once and the other twice, comparison of scores in each group yielded PEs. PEs were subtracted from each test to yield PE-adjusted scores. Biomarkers included cerebrospinal fluid phosphorylated tau and amyloid beta. Cox proportional models predicted time until first dementia diagnosis using PE-unadjusted and PE-adjusted diagnoses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Accounting for PEs increased MCI prevalence at follow-up by 9.2% (272 vs. 249 MCI), and reduced reversion to normal by 28.8% (57 vs. 80 reverters). PEs also increased stability of single-domain MCI by 12.0% (164 vs. 147). Compared to PE-unadjusted diagnoses, use of PE-adjusted follow-up diagnoses led to a twofold increase in hazard ratios for incident dementia. We classified individuals as false reverters if they reverted to cognitively unimpaired status based on PE-unadjusted scores, but remained classified as MCI cases after accounting for PEs. When amyloid and tau positivity were examined together, 72.2% of these false reverters were positive for at least one biomarker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Even when PEs are small, they can meaningfully change whether some individuals with MCI retain the diagnosis at a 1-year follow-up. Accounting for PEs resulted in increased MCI prevalence and altered stability\/reversion rates. This improved diagnostic accuracy also increased the dementia-predicting ability of MCI diagnoses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.847315","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T13:31:40Z","timestamp":1650893500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments"],"prefix":"10.3389","volume":"14","author":[{"given":"Mark","family":"Sanderson-Cimino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin M.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Panizzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Gustavson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Eppig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Kremen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility.","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2017.09.043","article-title":"The present and future of pharmacotherapy of Alzheimer\u2019s disease: a comprehensive review.","volume":"815","author":"Anand","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","article-title":"Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.","volume":"42","author":"Bondi","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the Pathologic Process in Alzheimer Disease: age Categories From 1 to 100 Years.","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/13854046.2012.680913","article-title":"Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment.","volume":"26","author":"Calamia","year":"2012","journal-title":"Clin. Neuropsychol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jamda.2016.06.020","article-title":"Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis.","volume":"17","author":"Canevelli","year":"2016","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures.","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria.","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/13854046.2014.920923","article-title":"One-week practice effects in older adults: tools for assessing cognitive change.","volume":"28","author":"Duff","year":"2014","journal-title":"Clin. Neuropsychol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/13854046.2020.1781933","article-title":"Practice effects in mild cognitive impairment: a validation of Calamia et al. (2012).","author":"Duff","year":"2020","journal-title":"Clin. Neuropsychol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000021","article-title":"Practice effects and amyloid deposition: preliminary data on a method for enriching samples in clinical trials.","volume":"28","author":"Duff","year":"2014","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/JGP.0b013e318209dd3a","article-title":"Practice effects predict cognitive outcome in amnestic mild cognitive impairment.","volume":"19","author":"Duff","year":"2011","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.trci.2017.11.001","article-title":"Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: a secondary analysis of the ADCS vitamin E and donepezil in MCI study.","volume":"4","author":"Edmonds","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jalz.2014.03.005","article-title":"Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.","volume":"11","author":"Edmonds","year":"","journal-title":"Alzheimers Dement."},{"key":"B16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-150128","article-title":"Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer\u2019s Disease.","volume":"47","author":"Edmonds","year":"","journal-title":"J. Alzheimers Dis. JAD"},{"key":"B17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.dadm.2018.04.003","article-title":"Underdiagnosis of mild cognitive impairment: a consequence of ignoring practice effects.","volume":"10","author":"Elman","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.biopsych.2019.12.021","article-title":"Amyloid-\u03b2 positivity predicts cognitive decline but cognition predicts progression to amyloid-\u03b2 positivity.","volume":"87","author":"Elman","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1017\/S135561771700039X","article-title":"Statistically derived subtypes and associations with cerebrospinal fluid and genetic biomarkers in mild cognitive impairment: a latent profile analysis.","volume":"23","author":"Eppig","year":"2017","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780190634230.003.0004","article-title":"Neuropsychological Contributions to the Diagnosis of Mild Cognitive Impairment Associated With Alzheimer\u2019s Disease. Vascular Disease","volume":"52","author":"Eppig","year":"2020","journal-title":"Alzheimer\u2019s Disease, and Mild Cognitive Impairment: advancing an Integrated Approach"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.dadm.2014.11.003","article-title":"Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer\u2019s disease randomized controlled trials.","volume":"1","author":"Goldberg","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/ageing\/afy136","article-title":"Do people with Alzheimer\u2019s disease improve with repeated testing? Unpacking the role of content and context in retest effects.","volume":"13","author":"Gross","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1017\/S1355617715000508","article-title":"Predictors of retest effects in a longitudinal study of cognitive aging in a diverse community-based sample.","volume":"21","author":"Gross","year":"2015","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts.","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B25","author":"Ho","year":"2018","journal-title":"Package \u2018MatchIt\u2019. Version 3."},{"key":"B26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease.","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","article-title":"Quantification of five neuropsychological approaches to defining mild cognitive impairment.","volume":"17","author":"Jak","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12055","article-title":"Lower practice effects as a marker of cognitive performance and dementia risk: a literature review.","volume":"12","author":"Jutten","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/wad.0000000000000145","article-title":"Reversion from mild cognitive impairment to normal cognition.","volume":"30","author":"Malek-Ahmadi","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.21326","article-title":"Frequency and course of mild cognitive impairment in a multiethnic community.","volume":"63","author":"Manly","year":"2008","journal-title":"Ann. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia\u2013meta-analysis of 41 robust inception cohort studies.","volume":"119","author":"Mitchell","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"B34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2016.07.055","article-title":"Does mild cognitive impairment always lead to dementia? A review.","volume":"369","author":"Pandya","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization.","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.intell.2005.06.004","article-title":"Adult life-span patterns in WAIS-R Block Design performance: cross-sectional versus longitudinal age gradients and relations to demographic factors.","volume":"34","author":"R\u00f6nnlund","year":"2006","journal-title":"Intelligence"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1037\/0882-7974.20.1.3","article-title":"Stability, growth, and decline in adult life span development of declarative memory: cross-sectional and longitudinal data from a population-based study.","volume":"20","author":"Ronnlund","year":"2005","journal-title":"Psychol. Aging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1017\/s1355617710000706","article-title":"Selective review of cognitive aging.","volume":"16","author":"Salthouse","year":"2010","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.03.20224808","article-title":"Cognitive Practice Effects Delay Diagnosis; Implications for Clinical Trials.","author":"Sanderson-Cimino","year":"2020","journal-title":"medRxiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects.","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt94","article-title":"A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery.","volume":"3","author":"Shirk","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials.","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1037\/neu0000694","article-title":"Application of neuropsychological criteria to classify mild cognitive impairment in the active study.","volume":"34","author":"Thomas","year":"2020","journal-title":"Neuropsychology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1017\/S1355617717000285","article-title":"Longitudinal trajectories of informant-reported daily functioning in empirically defined subtypes of mild cognitive impairment.","volume":"23","author":"Thomas","year":"2017","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jalz.2019.06.4948","article-title":"MCI-to-normal reversion using neuropsychological criteria in the Alzheimer\u2019s Disease Neuroimaging Initiative.","volume":"15","author":"Thomas","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative.","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228064","article-title":"Using practice effects for targeted trials or sub-group analysis in Alzheimer\u2019s disease: how practice effects predict change over time.","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.","volume":"256","author":"Winblad","year":"2004","journal-title":"J. Intern. Med."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.847315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T13:31:47Z","timestamp":1650893507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.847315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":50,"alternative-id":["10.3389\/fnagi.2022.847315"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.847315","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"847315"}}